Skip to Content
Merck
CN

Key Documents

View All Documentation

506600

Pamidronate, Disodium Salt

≥98% (HPLC), bone resorption inhibitor, solid

Synonym(s):

Pamidronate, Disodium Salt, 3-Amino-1-hydroxypropylidene-bisphosphonic Acid, 2Na, Pentahydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C3H9NO7P2 · 2Na · 5H2O
CAS Number:
109552-15-0
Molecular Weight:
369.11
MDL number:
MFCD01938386
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
OK to freeze, desiccated (hygroscopic)
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Pamidronate, Disodium Salt, A potent and specific inhibitor of bone resorption that does not cause any significant detrimental effect on bone growth and mineralization at concentrations used.

Quality Level

100

description

Merck USA index - 14, 7003

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, desiccated (hygroscopic)

color

white

solubility

water: 10 mg/mL

shipped in

ambient

storage temp.

−20°C

SMILES string

[Na+].[Na+].[P](=O)([O-])([O-])[C@@]([P](=O)([O-])O)(O)CC[N+H3].O.O.O.O.O

InChI

1S/C3H11NO7P2.2Na.5H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;;;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;5*1H2/q;2*+1;;;;;/p-2

InChI key

CZYWHNTUXNGDGR-UHFFFAOYSA-L

General description

A calcium metabolism regulator. A potent and specific inhibitor of bone resorption at doses devoid of any significant detrimental effect on bone growth and mineralization. Effective in a variety of conditions characterized by pathologically enhanced bone turnover, including Paget′s disease, hypercalcemia of malignancy, osteolytic bone metastasis, and steroid-induced cell death in vitro. Provided in a hydrated form containing five molecules of water.
A potent and specific inhibitor of bone resorption that does not cause any significant detrimental effect on bone growth and mineralization at concentrations used. Effective in a variety of conditions characterized by pathologically enhanced bone turnover, including Paget’s disease, hypercalcaemia of malignancy, osteolytic bone metastasis, steroid-induced osteoporosis, and idiopathic osteoporosis. Inhibits breast cancer cell growth by inducing cell death in vitro. Provided in hydrated form, contains five molecules of water.

Biochem/physiol Actions

Cell permeable: no
Primary Target
Inhibitor of bone resorption
Product does not compete with ATP.
Reversible: no

Preparation Note

Following reconstitution, refrigerate (4°C). Stock solutions are stable for up to 6 months at 4°C.

Other Notes

Fromigue, O., et al. 2000. J. Bone Miner. Res.15, 2211.
Fitton, A., and McTravish, D. 1991. Drugs41, 289.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H319

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

María A Günther Sillero et al.
FEBS letters, 580(24), 5723-5727 (2006-10-03)
T4 RNA ligase catalyzes the synthesis of ATP beta,gamma-bisphosphonate analogues, using the following substrates with the relative velocity rates indicated between brackets: methylenebisphosphonate (pCH(2)p) (100), clodronate (pCCl(2)p) (52), and etidronate (pC(OH)(CH(3))p) (4). The presence of pyrophosphatase about doubled the rate

Global Trade Item Number

SKUGTIN
506600-10MG04055977272482